News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

Wintermute Biomedical has successfully raised USD 1.3 million from investors to propel its groundbreaking Shingles treatment, Solexan™, into a Phase Ib clinical trial. The primary focus of this randomized double-blind placebo-controlled trial is to assess the safety, tolerability, and proof-of-concept efficacy of Solexan™ in reducing shingles-related pain and expediting lesion healing.

Golden Helix
|
February 29, 2024

Golden Helix, Inc. announced that it has received the certification for ISO 13485:2016 from TÜV SÜD. ISO 13485:2016 is an international standard that specifies requirements for a quality management system (QMS) for organizations involved in the design, development, production, and servicing of medical devices. 

Golden Helix
|
February 18, 2024

Golden Helix, Inc. announced that it has received the certification for ISO 13485:2016 from TÜV SÜD. ISO 13485:2016 is an international standard that specifies requirements for a quality management system (QMS) for organizations involved in the design, development, production, and servicing of medical devices. It is specifically tailored to the medical device industry and is recognized globally as a benchmark for ensuring the quality and safety of medical devices.

Montana State University
|
February 12, 2024

The National Institutes of Health recently awarded a Montana State University doctoral student a prestigious Graduate Partnership Program Fellowship. Through the fellowship, Jonathan Shikany, a second-year doctoral student in MSU’s Department of Chemical and Biological Engineering in the Norm Asbjornson College of Engineering, will receive funding for tuition and living expenses as he completes his degree, as well as funding to cover research-related expenses.  

McLaughlin Research Institute
|
February 11, 2024

The grant money will launch the Center for Integrated Biomedical and Rural Health Research or CIB-RHR, expanding the research enterprise over the next five years, with the ultimate hope of bringing healthcare improvements to the state.

ARTICLES OF INTEREST

BIO.News
|
January 30, 2024

As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.

NIH National Institute on Aging
|
January 18, 2024

Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR

National Institutes of Health SEED
|
January 18, 2024

Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.

National Institutes of Health
|
January 14, 2024

Updates from product development and small business programs

Bio
|
December 11, 2023

The wait is finally over as the Biotechnology Innovation Organization (BIO) taps John F. Crowley, a longtime leader and tireless patient advocate in the biotech industry, to fill the role of the organization’s new CEO.

NEWSLETTER

Newsletter
|
February 20, 2024

View the Winter II 2024 Newsletter now!

Newsletter
|
December 21, 2023

View the Winter 2023 Newsletter now!